Influx Healthtech IPO

About Influx Healthtech IPO

Influx Healthtech IPO is a book-built issue worth ₹58.57 crore. The IPO consists of a combination of a fresh issue of 50.00 lakh shares aggregating to ₹48.00 crores and an offer for sale of 11.00 lakh shares aggregating to ₹10.56 crores. The IPO opens for subscription on June 18, 2025, and closes on June 20, 2025. The allotment is expected to be finalised on June 23, 2025, with tentative listing on NSE SME scheduled for June 25, 2025.

The IPO is priced in a band of ₹91 – ₹96 per share. Retail investors must apply for a minimum of 1 lot comprising 1200 shares, requiring an investment of ₹1,15,200 at the cutoff price. HNI investors must apply for a minimum of 2 lots (2400 shares), amounting to ₹2,30,400.

Rarever Financial Advisors Private Limited is the book-running lead manager to the issue, and Maashitla Securities Private Limited is the registrar. The market maker for the Influx Healthtech IPO is R.K. Stockholding Private Limited.

For detailed information on company financials, business operations, and associated risks, investors are advised to refer to the Influx Healthtech IPO RHP.

Industry Outlook

1. India’s nutraceutical and wellness industry is experiencing robust growth, underpinned by rising health consciousness, increasing disposable incomes, and a shift towards preventive healthcare. The sector encompasses dietary supplements, functional foods, herbal products, and fortified beverages, and is increasingly being integrated into mainstream health and lifestyle regimes.
2. The Indian nutraceutical market, valued at approximately USD 6 billion in 2022, is projected to grow at a CAGR of over 15% through 2030. This expansion is driven by a confluence of factors, including urbanisation, a growing middle class, and heightened awareness of lifestyle-related disorders. Government initiatives such as the Ayushman Bharat scheme and the promotion of traditional medicine systems under the Ministry of AYUSH are further catalysing demand for herbal and Ayurvedic formulations.
3. The contract development and manufacturing organisation (CDMO) model, as adopted by Influx Healthtech, is gaining traction due to its cost efficiency, scalability, and regulatory compliance. This model allows brand owners to focus on marketing and distribution while outsourcing production to specialised manufacturers with GMP, HACCP, and ISO-certified facilities.
4. The competitive landscape is evolving rapidly, with both domestic and international players investing in R&D, automation, and product innovation. Key differentiators include formulation expertise, speed to market, and the ability to cater to diverse product formats such as tablets, capsules, gummies, and oral dispersible films.

Influx Healthtech IPO Objectives

The company proposes to utilise the net proceeds from the IPO for the following objectives:

1. Augment working capital reserves to support the company’s expanding manufacturing operations, ensuring uninterrupted procurement of raw materials, streamlined production cycles, and enhanced liquidity management.
2. Invest in capital expenditure for the installation of advanced machinery at its Greater Noida facility, thereby increasing production capacity and enabling the company to meet rising demand for electronic energy meters.
3. Address general corporate requirements, including administrative expenses, brand development, and strategic initiatives aimed at operational efficiency and long-term sustainability.
4. Elevate corporate visibility and market credibility through public listing, facilitating broader investor engagement and enabling future capital mobilisation and strategic collaborations.

About Influx Healthtech Limited

Influx Healthtech Limited was originally incorporated as Influx Healthtech Private Limited on 28 September 2020 under the Companies Act, 2013. It was subsequently converted into a public limited company and renamed Influx Healthtech Limited on 23 May 2022.

The company operates as a Contract Development and Manufacturing Organisation (CDMO), specialising in the production of dietary and nutritional supplements, cosmetics, Ayurvedic and herbal formulations, veterinary feed supplements, homecare products, and active pharmaceutical ingredients (APIs). Its product portfolio includes tablets, capsules, injectables, oral dispersible films, protein bars, and ready-to-drink nutraceutical beverages.

Influx Healthtech manages three manufacturing facilities in Thane, Maharashtra, with a combined area of approximately 36,676 square feet. These facilities are certified to international standards, including GMP, HACCP, ISO 22000, and Halal, ensuring high levels of quality, safety, and regulatory compliance.

The company’s operations are primarily focused within India, with a strong presence in Maharashtra, Gujarat, and Karnataka. Its customer base spans across B2B clients in the health, wellness, and pharmaceutical sectors, with a growing emphasis on private label manufacturing and export opportunities.

With a commitment to innovation, automation, and product diversification, Influx Healthtech Limited aims to scale its operations through strategic capital investment, enhanced production capabilities, and a broader product mix. The company’s growth strategy is anchored in operational excellence, regulatory adherence, and responsiveness to evolving consumer health trends.

How To Check the Allotment Status of the Influx Healthtech IPO?

Steps to check IPO allotment status on Angel One’s app:

1. Log in to the Angel One app.
2. Go to the IPO Section and then to IPO Orders.
3. Select the individual IPO that you had applied for and check the allotment status.
4. Angel One will notify you of your IPO allotment status via push notification and email.

How To Apply for Influx Healthtech IPO Online?

1. Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
2. Locate the IPO Section: Navigate to the 'IPO' section on the platform.
3. Select IPO: Find and select the Influx Healthtech IPO from the list of open IPOs.
4. Enter the Lot Size: Specify the number of lots you want to bid for.
5. Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
6. Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.

Contact Details of Influx Healthtech IPO

Registered office: 109, Ghanshyam Enclave Premises Co-op Soc., Plot No. 856, Laljipada, Kandivali West, Mumbai – 400067, Maharashtra, India.

Phone: +91 70459 97809

E-mail: cs@influxhealthtech.com

Influx Healthtech IPO Reservation

Influx Healthtech IPO Lot Size

Influx Healthtech IPO Promoter Holding

The promoters of the company are Mr. Munir Abdul Ganee Chandniwala, Mrs. Shirin Munir Ahmed Chandniwala and Mr. Abdul Ganee Abdul Rasul Chandniwala.